332 related articles for article (PubMed ID: 23845143)
1. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
2. INDQ/NO, a bioreductively activated nitric oxide prodrug.
Sharma K; Iyer A; Sengupta K; Chakrapani H
Org Lett; 2013 Jun; 15(11):2636-9. PubMed ID: 23659457
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
4. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
Meng F; Evans JW; Bhupathi D; Banica M; Lan L; Lorente G; Duan JX; Cai X; Mowday AM; Guise CP; Maroz A; Anderson RF; Patterson AV; Stachelek GC; Glazer PM; Matteucci MD; Hart CP
Mol Cancer Ther; 2012 Mar; 11(3):740-51. PubMed ID: 22147748
[TBL] [Abstract][Full Text] [Related]
5. The role of hypoxia-activated prodrugs in cancer therapy.
Denny WA
Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
[No Abstract] [Full Text] [Related]
7. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
9. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
10. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria-targeting multifunctional nanoplatform for cascade phototherapy and hypoxia-activated chemotherapy.
Lv J; Wang S; Qiao D; Lin Y; Hu S; Li M
J Nanobiotechnology; 2022 Jan; 20(1):42. PubMed ID: 35062959
[TBL] [Abstract][Full Text] [Related]
13. Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Johnson KM; Parsons ZD; Barnes CL; Gates KS
J Org Chem; 2014 Aug; 79(16):7520-31. PubMed ID: 25029663
[TBL] [Abstract][Full Text] [Related]
14. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
17. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
Lohse I; Rasowski J; Cao P; Pintilie M; Do T; Tsao MS; Hill RP; Hedley DW
Oncotarget; 2016 Jun; 7(23):33571-80. PubMed ID: 27248663
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
[TBL] [Abstract][Full Text] [Related]
19. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs.
Parker LL; Lacy SM; Farrugia LJ; Evans C; Robins DJ; O'Hare CC; Hartley JA; Jaffar M; Stratford IJ
J Med Chem; 2004 Nov; 47(23):5683-9. PubMed ID: 15509167
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
